Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease. 2017

Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy. comi@med.uniupo.it.

L-dopa-induced dyskinesia (LID) is a frequent motor complication of Parkinson's disease (PD), associated with a negative prognosis. Previous studies showed an association between dopamine receptor (DR) gene (DR) variants and LID, the results of which have not been confirmed. The present study is aimed to determine whether genetic differences of DR are associated with LID in a small but well-characterized cohort of PD patients. To this end we enrolled 100 PD subjects, 50 with and 50 without LID, matched for age, gender, disease duration and dopaminergic medication in a case-control study. We conducted polymerase chain reaction for single nucleotide polymorphisms (SNP) in both D1-like (DRD1A48G; DRD1C62T and DRD5T798C) and D2-like DR (DRD2G2137A, DRD2C957T, DRD3G25A, DRD3G712C, DRD4C616G and DRD4nR VNTR 48bp) analyzed genomic DNA. Our results showed that PD patients carrying allele A at DRD3G3127A had an increased risk of LID (OR 4.9; 95% CI 1.7-13.9; p = 0.004). The present findings may provide valuable information for personalizing pharmacological therapy in PD patients.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
March 2021, Biomedicines,
Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
December 2013, CNS & neurological disorders drug targets,
Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
January 2015, Bulletin de l'Academie nationale de medecine,
Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
January 2014, PloS one,
Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
August 2020, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
August 2009, Neurobiology of disease,
Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
January 2012, Parkinsonism & related disorders,
Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
December 2009, Parkinsonism & related disorders,
Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
January 2013, Pharmacological reviews,
Cristoforo Comi, and Marco Ferrari, and Franca Marino, and Luca Magistrelli, and Roberto Cantello, and Giulio Riboldazzi, and Maria Laura Ester Bianchi, and Giorgio Bono, and Marco Cosentino
July 2018, Movement disorders : official journal of the Movement Disorder Society,
Copied contents to your clipboard!